Yi Hu

15.6k total citations · 4 hit papers
314 papers, 4.9k citations indexed

About

Yi Hu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yi Hu has authored 314 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 169 papers in Oncology, 135 papers in Pulmonary and Respiratory Medicine and 94 papers in Molecular Biology. Recurrent topics in Yi Hu's work include Lung Cancer Treatments and Mutations (77 papers), Cancer Immunotherapy and Biomarkers (69 papers) and Lung Cancer Research Studies (43 papers). Yi Hu is often cited by papers focused on Lung Cancer Treatments and Mutations (77 papers), Cancer Immunotherapy and Biomarkers (69 papers) and Lung Cancer Research Studies (43 papers). Yi Hu collaborates with scholars based in China, United States and United Kingdom. Yi Hu's co-authors include Yangzhe Wu, Haitao Tao, Jinliang Wang, Shunchang Jiao, Yixue Xue, Sujie Zhang, Yijia Li, Zhibo Zhang, Junxun Ma and Jing Liu and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Yi Hu

288 papers receiving 4.9k citations

Hit Papers

Temporal single-cell tracing reveals clonal revival and e... 2021 2026 2022 2024 2021 2022 2023 2024 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer
    2021 253 citations Yi Hu et al. profile →
  2. Programmed Cell Death Tunes Tumor Immunity
    2022 231 citations Yi Hu et al. Frontiers in Immunology profile →
  3. γδ T cells: origin and fate, subsets, diseases and immunotherapy
    2023 152 citations Yi Hu et al. profile →
  4. The association between triglyceride glucose-body mass index and all-cause mortality in critically ill patients with atrial fibrillation: a retrospective study from MIMIC-IV database
    2024 41 citations Yi Hu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yi Hu China 35 2.2k 1.8k 1.3k 1.1k 884 314 4.9k
Xinwei Han China 34 1.8k 0.8× 1.7k 1.0× 1.4k 1.1× 999 0.9× 972 1.1× 175 4.6k
Tangfeng Lv China 37 1.7k 0.8× 2.7k 1.5× 1.5k 1.2× 1.3k 1.3× 736 0.8× 219 5.1k
Kazuaki Tanabe Japan 35 1.6k 0.7× 1.8k 1.0× 1.4k 1.1× 542 0.5× 1.3k 1.5× 153 5.2k
Takayuki Ueno Japan 33 1.7k 0.8× 1.4k 0.8× 671 0.5× 996 0.9× 569 0.6× 186 3.9k
Pei‐Yi Chu Taiwan 37 1.5k 0.7× 2.6k 1.4× 726 0.6× 1.1k 1.1× 651 0.7× 210 4.7k
Julie E. Bauman United States 36 2.7k 1.2× 2.6k 1.4× 1.6k 1.2× 1.2k 1.2× 815 0.9× 140 6.6k
Konstantinos N. Syrigos Greece 42 2.7k 1.2× 2.0k 1.1× 1.7k 1.3× 754 0.7× 838 0.9× 198 5.7k
Kaixiong Tao China 39 1.3k 0.6× 2.4k 1.3× 993 0.8× 1.0k 1.0× 644 0.7× 285 5.2k
Rajkumar Savai Germany 42 1.2k 0.6× 2.5k 1.4× 2.1k 1.6× 1.2k 1.2× 1.4k 1.5× 124 5.5k
Wei Guo China 35 1.2k 0.6× 2.3k 1.3× 824 0.6× 1.1k 1.0× 488 0.6× 174 4.2k

Countries citing papers authored by Yi Hu

Since Specialization
Citations

This map shows the geographic impact of Yi Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yi Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yi Hu more than expected).

Fields of papers citing papers by Yi Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yi Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yi Hu. The network helps show where Yi Hu may publish in the future.

Co-authorship network of co-authors of Yi Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Yi Hu. A scholar is included among the top collaborators of Yi Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yi Hu. Yi Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
McDanel, Bradley, Sai Qian Zhang, Yi Hu, & Zining Liu. (2025). PipeSpec: Breaking Stage Dependencies in Hierarchical LLM Decoding. 12909–12920. 1 indexed citations
2.
Wang, Shi‐Ping, et al.. (2024). Study on load characteristics and structural impact response propagation law of cabin internal explosion. Ocean Engineering. 301. 117582–117582. 7 indexed citations
3.
4.
5.
Wang, Xiaoman, et al.. (2024). Electrochemical Synthesis of Alkenylsulfonates from Alkynes, NaHSO3 and Alcohols. Chinese Journal of Chemistry. 43(3). 292–296. 8 indexed citations
6.
Fan, Chengjuan, Che‐Ming Teng, Xiaowei Song, et al.. (2024). Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial. ESMO Open. 9(4). 102384–102384. 16 indexed citations
7.
Tang, Zhe, Yong Shi, Zhiting Deng, et al.. (2024). Effects of Corbicula fluminea meal in high-fat diet on growth, lipid metabolism and intestinal microbiota of juvenile rice field eel Monopterus albus. Aquaculture. 590. 741064–741064. 9 indexed citations
8.
9.
10.
Li, Tao, Wenyu Yang, Tingting Liu, et al.. (2023). Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China. Technology in Cancer Research & Treatment. 22. 2213890690–2213890690. 2 indexed citations
11.
She, Han, Lei Tan, Yi Wang, et al.. (2023). Integrative single-cell RNA sequencing and metabolomics decipher the imbalanced lipid-metabolism in maladaptive immune responses during sepsis. Frontiers in Immunology. 14. 1181697–1181697. 23 indexed citations
12.
Bai, Yibing, Haitao Tao, Fan Zhang, et al.. (2023). Prediction model for hyperprogressive disease in patients with advanced solid tumors received immune-checkpoint inhibitors: a pan-cancer study. Cancer Cell International. 23(1). 224–224. 2 indexed citations
13.
Zhao, Mengmeng, Ning Lyu, Sheng Zhong, et al.. (2023). 983P Safety and efficacy of durvalumab plus hepatic artery infusion chemotherapy in HCC with severe portal vein tumor thrombosis (Vp3/4) – the DurHope study. Annals of Oncology. 34. S608–S608. 3 indexed citations
14.
Hu, Yi, et al.. (2023). EE266 Societal Economic Impact of Treatment with Adjuvant Osimertinib in Patients with Early-Stage (IB-IIIA) EGFRm NSCLC. Value in Health. 26(6). S107–S107. 1 indexed citations
15.
Zhou, Caicun, Yi Hu, Kejing Ying, et al.. (2023). 540P Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup. Annals of Oncology. 34. S1680–S1680. 1 indexed citations
16.
Li, Lanlan, Yi Hu, Pengfei Wang, et al.. (2023). Site-specific inhibition of neutrophilic inflammation by low-dose nanotherapy for immunoregulatory treatment of asthma. Nano Today. 52. 101957–101957. 9 indexed citations
17.
Cheng, Gang, et al.. (2020). Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial. SHILAP Revista de lepidopterología. 1 indexed citations
18.
19.
Hu, Yi, et al.. (2019). Expression profile and prognostic value of SFN in human ovarian cancer. Bioscience Reports. 39(5). 20 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xinwei Han Breakdown of academic impact, for papers by Tangfeng Lv Breakdown of academic impact, for papers by Kazuaki Tanabe Breakdown of academic impact, for papers by Takayuki Ueno Breakdown of academic impact, for papers by Pei‐Yi Chu Breakdown of academic impact, for papers by Julie E. Bauman Breakdown of academic impact, for papers by Konstantinos N. Syrigos Breakdown of academic impact, for papers by Kaixiong Tao Breakdown of academic impact, for papers by Rajkumar Savai Breakdown of academic impact, for papers by Wei Guo
Rankless by CCL
2026